Neoprobe Elects Gordon Troup Chairman of the Board
16 Agosto 2011 - 7:30AM
Business Wire
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer
of innovative oncology surgical and diagnostic products, today
announced that Gordon A. Troup was elected Chairman of the Board at
a meeting of the Board of Directors held following the Company’s
2011 Annual Meeting of Stockholders. Mr. Troup succeeds Carl J.
Aschinger, Jr., who has served as a director of our Company since
June 2004 and as Chairman of the Board since July 2007.
"Gordon is an innovative, forward-thinking leader and has been a
positive influence for the Company since joining the Board, and I
am very pleased that he succeeds me as Chairman," Mr. Aschinger
said. "He has played an important role in helping evaluate our
growth strategy and in guiding us during this pivotal period in our
Company’s history. His experience will serve the Company well as
Neoprobe continues its transformation into a pure-play specialty
radiopharmaceutical development and commercialization entity."
"In my time with Neoprobe, I have witnessed the beginning of an
evolution of an entrepreneurial company with a niche medical device
business and development stage radiopharmaceuticals into a company
poised to become a lead player in the radiopharmaceutical space,"
Mr. Troup said. "Carl’s leadership and stewardship are evident in
the enormous accomplishments at Neoprobe during the last several
years and I thank him for his tremendous contribution as we look
forward to getting Lymphoseek® over the goal line of FDA
approval."
Mr. Troup has served as a director of Neoprobe since July 2008
and as Vice Chairman of the Board since July 2010. He served as
President of the Nuclear Pharmacy Services business at Cardinal
Health, Inc. (Cardinal Health), a multinational medical products
and services company, from January 2003 until his retirement in
December 2007. Mr. Troup joined Cardinal Health in 1990 and was
appointed Group President of Pharmaceutical Distribution and
Specialty Distribution Services in 1999. Prior to joining Cardinal
Health, Mr. Troup was employed for ten years by American Hospital
Supply Corporation and three years by Zellerbach Paper, a Mead
Company. Mr. Troup has a B.S. degree in Business Management from
San Diego State University.
"Carl’s vision and leadership guided Neoprobe from a small
bulletin board company into an exchange-listed company on the verge
of commercial success. We are fortunate to have had his counsel and
guidance during the last several years," said Dr. Mark Pykett,
President and Chief Executive Officer of Neoprobe. "I have also
enjoyed working with Gordon as an active director and look forward
to his new role as Chairman as we continue to build the Neoprobe
business."
About Neoprobe
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company
focused on development of precision diagnostics that enhance
patient care and improve patient benefit. Neoprobe is actively
developing and commercializing targeted agents aimed at the
identification of occult (undetected) disease. The Company’s two
lead radiopharmaceutical agent platforms – Lymphoseek® and RIGScan™
– are intended to help surgeons better identify and treat certain
types of cancer. In achieving its goals, Neoprobe’s business model
leverages collaborations and partnerships with world-class
institutions, manufacturing concerns and distribution entities.
Neoprobe’s strategy is to deliver superior growth and stockholder
return by bringing to market novel radiopharmaceutical agents and
advancing the Company’s pipeline programs through continued
investment and selective acquisition or in-licensing of
complementary technologies. For more information, please visit
www.neoprobe.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024